

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-38. (Cancelled)

39. (Currently amended) A recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter, wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage site of said autocatalytically cleaving ribozyme is located between said first and second arms, and wherein the sum of the number of nucleotides of said first and second arms is from 25 nucleotides or more to 53 nucleotides.

40. (Previously presented) The recombinant nucleic acid of claim 39, wherein said nucleotide sequence encodes a pChop cassette.

41. (Previously presented) The recombinant nucleic acid of claim 39, wherein said nucleotide sequence encodes a pSnip cassette.

42. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid comprises an origin of replication.

43. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes more than one trans-acting ribozyme.
44. (Previously presented) The recombinant nucleic acid of claim 43, wherein the trans-acting ribozymes are targeted to different sites on the same target-RNA.
45. (Previously presented) The recombinant nucleic acid of claim 43, wherein the trans-acting ribozymes are targeted to different target-RNAs.
46. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes more than one ribozyme cassette.
47. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes at least two different ribozymes cassettes.
48. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes more than one copy of a ribozyme cassette.
49. (Previously presented) The recombinant nucleic acid of claim 39, wherein said trans-acting ribozyme is targeted to a transcript selected from the group consisting of: pol II, HBV, pol III, RB, IGF1, SH, pol I, HPV, C3, C9, B2, Tel, TGF β , CAT, PpaR α , p4501E1, AR, and SF1 transcripts.
50. (Previously presented) The recombinant nucleic acid of claim 39, wherein said nucleotide sequence encodes a hairpin loop.
51. (Previously presented) The recombinant nucleic acid of claim 39, wherein said nucleotide sequence encodes multiple ribozyme cassettes linked together by at least 4

nucleotides.

52. (Previously presented) The recombinant nucleic acid of claim 39, wherein said tissue-specific promoter is a K4 promoter, K7 promoter, K13 promoter or albumin promoter.

53. (Currently amended) An isolated A cell containing a recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter, wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage site of said autocatalytically cleaving ribozyme is located between said first and second arms, and wherein the sum of the number of nucleotides of said first and second arms is from 25 nucleotides or more to 53 nucleotides.

54. (Currently amended) A virion comprising a recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter, wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage site of said autocatalytically cleaving ribozyme is located between said first and second arms, and wherein the sum of the number of nucleotides of said first and second arms is from 25 nucleotides or more to 53 nucleotides.

55. (Currently amended) A liposome composition comprising a recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter, wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage

Applicant : James S. Norris et al.
Serial No. : 10/082,973
Filed : February 26, 2002
Page : 5 of 8

Attorney's Docket No.: 14017-004002 / PSU 96-1566

site of said autocatalytically cleaving ribozyme is located between said first and second arms,
and wherein the sum of the number of nucleotides of said first and second arms is from 25
nucleotides ~~or more~~ to 53 nucleotides.